Serum uric acid and the risk of mortality during 23 years follow-up in the Scottish heart health extended cohort study

Atherosclerosis

Volumn 233, Issue 2, 2014, Pages 623-629

  Juraschek, Stephen P ^a,b,c   Tunstall Pedoe, Hugh ^d   Woodward, Mark ^a,b,d,e  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

Author keywords

Cancer; Cardiovascular disease; Cohort; Hyperuricemia; Kidney disease; Mortality; Scottish heart health extended cohort (SHHEC); Uric acid

Indexed keywords

URIC ACID;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; FEMALE; FOLLOW UP; HEART DEATH; HUMAN; HYPERURICEMIA; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SEX DIFFERENCE; UNITED KINGDOM; URIC ACID BLOOD LEVEL; AGED; BLOOD; CAUSE OF DEATH; CLINICAL TRIAL; DIABETES MELLITUS; DYSLIPIDEMIAS; EPIDEMIOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK FACTOR; SMOKING;

ADULT; AGED; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERURICEMIA; KAPLAN-MEIER ESTIMATE; KIDNEY DISEASES; MALE; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SCOTLAND; SMOKING; URIC ACID;

EID: 84896285653     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.01.026     Document Type: Article

References (78)

1. Juraschek S.P., Kovell L.C., Miller E.R., Gelber A.C. Dose-response association of uncontrolled blood pressure and cardiovascular disease risk factors with hyperuricemia and gout. PLoS ONE 2013, 8:e56546.
2. Nieto F.J., Iribarren C., Gross M.D., Comstock G.W., Cutler R.G. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis?. Atherosclerosis 2000, 148:131-139.
3. Ames B.N., Cathcart R., Schwiers E., Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 1981, 78:6858-6862.
4. Kim S.Y., De Vera M.A., Choi H.K. Gout and mortality. Clin Exp Rheumatol 2008, 26:S115-S119.
5. Tomita M., Mizuno S., Yamanaka H., et al. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. JEpidemiol 2000, 10:403-409.
6. Niskanen L.K., Laaksonen D.E., Nyyssönen K., et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004, 164:1546-1551.
7. Levine W., Dyer A.R., Shekelle R.B., Schoenberger J.A., Stamler J. Serum uric acid and 11.5-year mortality of middle-aged women: findings of the Chicago Heart Association Detection Project in Industry. JClin Epidemiol 1989, 42:257-267.
8. Freedman D.S., Williamson D.F., Gunter E.W., Byers T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1995, 141:637-644.
9. Franse L.V., Pahor M., Di Bari M., et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). JHypertens 2000, 18:1149-1154.
10. Jee S.H., Lee S.Y., Kim M.T. Serum uric acid and risk of death from cancer, cardiovascular disease or all causes in men. Eur J Cardiovasc Prev Rehabil 2004, 11:185-191.
11. Takkunen H., Reunanen A., Aromaa A., Knekt P. Raised serum urate concentration as risk factor for premature mortality in middle aged men. Br Med J Clin Res Ed 1984, 288:1161.
12. Ndrepepa G., Braun S., King L., et al. Uric acid and prognosis in angiography-proven coronary artery disease. Eur J Clin Invest 2013, 43:256-266.
13. Smith W.C., Crombie I.K., Tavendale R., Irving J.M., Kenicer M.B., Tunstall Pedoe H. The Scottish Heart Health Study: objectives and development of methods. Health Bull (Edinb) 1987, 45:211-217.
14. Tunstall-Pedoe H., Woodward M., Tavendale R., A'Brook R., McCluskey M.K. Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish Heart Health Study: cohort study. BMJ 1997, 315:722-729.
15. Woodward M., Brindle P., Tunstall-Pedoe H. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart 2007, 93:172-176. for SIGN group on risk estimation.
16. For the WHO MONICA Project. MONICA monograph and multimedia sourcebook 2003, World Health Organization, Geneva, n.d. H. Tunstall-Pedoe (Ed.).
17. Kendrick S., Clarke J. The Scottish record linkage system. Health Bull (Edinb) 1993, 51:72-79.
18. Bais R., White R.G., Elston D., Geary T.D. Assessment of the Cobas Bio centrifugal analyser. JAutom Chem 1982, 4:21-24.
19. Feig D.I., Kang D.-H., Johnson R.J. Uric acid and cardiovascular risk. NEngl J Med 2008, 359:1811-1821.
20. Scottish Executive SAH Scottish Index of multiple deprivation 2011.
21. Levey A.S., Stevens L.A., Schmid C.H., et al. Anew equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150:604-612.
22. Sorensen L.B., Levinson D.J. Origin and extrarenal elimination of uric acid in man. Nephron 1975, 14:7-20.
23. Rieselbach R.E. Renal handling of uric acid. Adv Exp Med Biol 1977, 76B:1-22.
24. Choi J.W.J., Ford E.S., Gao X., Choi H.K. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2008, 59:109-116.
25. Brecher A.S., Lehti M.D. Ahypothesis linking hypoglycemia, hyperuricemia, lactic acidemia, and reduced gluconeogenesis in alcoholics to inactivation of glucose-6-phosphatase activity by acetaldehyde. Alcohol 1996, 13:553-557.
26. Ultmann J.E. Hyperuricemia in disseminated neoplastic disease other than lymphomas and leukemias. Cancer 1962, 15:122-129.
27. Juraschek S.P., Kovell L.C., Miller E.R., Gelber A.C. Association of kidney disease with prevalent gout in the United States in 1988-1994 and 2007-2010. Semin Arthritis Rheum 2013, 10.1016/j.semarthrit.2012.09.009.
28. Peden D.B., Hohman R., Brown M.E., et al. Uric acid is a major antioxidant in human nasal airway secretions. Proc Natl Acad Sci U S A 1990, 87:7638-7642.
29. Madero M., Sarnak M.J., Wang X., et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis 2009, 53:796-803.
30. Jeemon P., Prabhakaran D. Does uric acid qualify as an independent risk factor for cardiovascular mortality?. Clin Sci 2013, 124:255-257.
31. Ioannou G.N., Boyko E.J. Effects of menopause and hormone replacement therapy on the associations of hyperuricemia with mortality. Atherosclerosis 2013, 226:220-227.
32. Hakoda M., Masunari N., Yamada M., et al. Serum uric acid concentration as a risk factor for cardiovascular mortality: a longterm cohort study of atomic bomb survivors. JRheumatol 2005, 32:906-912.
33. Chen J.-H., Chuang S.-Y., Chen H.-J., Yeh W.-T., Pan W.-H. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum 2009, 61:225-232.
34. Fang J., Alderman M.H. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000, 283:2404-2410.
35. Reunanen A., Takkunen H., Knekt P., Aromaa A. Hyperuricemia as a risk factor for cardiovascular mortality. Acta Med Scand Suppl 1982, 668:49-59.
36. Høieggen A., Alderman M.H., Kjeldsen S.E., et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004, 65:1041-1049.
37. Nicholls A., Snaith M.L., Scott J.T. Effect of oestrogen therapy on plasma and urinary levels of uric acid. Br Med J 1973, 1:449-451.
38. Sumino H., Ichikawa S., Kanda T., Nakamura T., Sakamaki T. Reduction of serum uric acid by hormone replacement therapy in postmenopausal women with hyperuricaemia. Lancet 1999, 354:650.
39. Culleton B.F., Larson M.G., Kannel W.B., Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999, 131:7-13.
40. Juraschek S.P., McAdams-Demarco M., Miller E.R., et al. Temporal relationship between uric acid and diabetes in a community-based population. Am J Epidemiol 2014, PMID: 24418684.
41. Boner G., Rieselbach R.E. The effect of glucose upon reabsorptive transport of urate by the kidney. Adv Exp Med Biol 1974, 41:781-787.
42. Facchini F., Chen Y.D., Hollenbeck C.B., Reaven G.M. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991, 266:3008-3011.
43. Teng F., Zhu R., Zou C., et al. Interaction between serum uric acid and triglycerides in relation to blood pressure. JHum Hypertens 2011, 25:686-691.
44. Ekundayo O.J., Dell'Italia L.J., Sanders P.W., et al. Association between hyperuricemia and incident heart failure among older adults: a propensity-matched study. Int J Cardiol 2010, 142:279-287.
45. Holme I., Aastveit A.H., Hammar N., Jungner I., Walldius G. Lipoprotein components and risk of congestive heart failure in 84,740 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). Eur J Heart Fail 2009, 11:1036-1042.
46. Strasak A.M., Kelleher C.C., Brant L.J., et al. Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28,613 elderly women: a prospective 21-year follow-up study. Int J Cardiol 2008, 125:232-239.
47. Strasak A., Ruttmann E., Brant L., et al. Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Austrian men. Clin Chem 2008, 54:273-284.
48. Tian Y., Chen Y., Deng B., et al. Serum uric acid as an index of impaired renal function in congestive heart failure. JGeriatr Cardiol 2012, 9:137-142.
49. Kang D.-H., Park S.-K., Lee I.-K., Johnson R.J. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. JAm Soc Nephrol 2005, 16:3553-3562.
50. Choi H.K., Ford E.S. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007, 120:442-447.
51. Petersson B., Trell E. Raised serum urate concentration as risk factor for premature mortality in middle aged men: relation to death from cancer. Br Med J Clin Res Ed 1983, 287:7-9.
52. Hammarsten J., Damber J.-E., Peeker R., Mellström D., Högstedt B. Ahigher prediagnostic insulin level is a prospective risk factor for incident prostate cancer. Cancer Epidemiol 2010, 34:574-579.
53. Kolonel L.N., Yoshizawa C., Nomura A.M., Stemmermann G.N. Relationship of serum uric acid to cancer occurrence in a prospective male cohort. Cancer Epidemiol Biomarkers Prev 1994, 3:225-228.
54. Strasak A.M., Rapp K., Hilbe W., et al. The role of serum uric acid as an antioxidant protecting against cancer: prospective study in more than 28 000 older Austrian women. Ann Oncol 2007, 18:1893-1897.
55. Strasak A.M., Rapp K., Hilbe W., et al. Serum uric acid and risk of cancer mortality in a large prospective male cohort. Cancer Causes Control 2007, 18:1021-1029.
56. Shin H.-S., Lee H.-R., Lee D.-C., Shim J.-Y., Cho K.-H., Suh S.-Y. Uric acid as a prognostic factor for survival time: a prospective cohort study of terminally ill cancer patients. JPain Symptom Manag 2006, 31:493-501.
57. Hiatt R.A., Fireman B.H. Serum uric acid unrelated to cancer incidence in humans. Cancer Res 1988, 48:2916-2918.
58. Bozkir A., Simşek B., Güngört A., Torun M. Ascorbic acid and uric acid levels in lung cancer patients. JClin Pharm Ther 1999, 24:43-47.
59. Shi Y., Evans J.E., Rock K.L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003, 425:516-521.
60. Ullrich E., Ménard C., Flament C., et al. Dendritic cells and innate defense against tumor cells. Cytokine Growth Factor Rev 2008, 19:79-92.
61. Fessel W.J. Renal outcomes of gout and hyperuricemia. Am J Med 1979, 67:74-82.
62. Navaneethan S.D., Beddhu S. Associations of serum uric acid with cardiovascular events and mortality in moderate chronic kidney disease. Nephrol Dial Transpl 2009, 24:1260-1266.
63. Iseki K., Oshiro S., Tozawa M., Iseki C., Ikemiya Y., Takishita S. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res 2001, 24:691-697.
64. Syrjänen J., Mustonen J., Pasternack A. Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transpl 2000, 15:34-42.
65. Bo S., Cavallo-Perin P., Gentile L., Repetti E., Pagano G. Hypouricemia and hyperuricemia in type 2 diabetes: two different phenotypes. Eur J Clin Invest 2001, 31:318-321.
66. Ohno I., Hosoya T., Gomi H., Ichida K., Okabe H., Hikita M. Serum uric acid and renal prognosis in patients with IgA nephropathy. Nephron 2001, 87:333-339.
67. Chonchol M., Shlipak M.G., Katz R., et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 2007, 50:239-247.
68. Wang F., Zhang L., Zuo L., Liu L., Wang H. Mortality and renal function decline among a community-based Chinese population with normal or mildly impaired renal function. Nephrol Dial Transpl 2011, 26:2847-2852.
69. Liu W.-C., Hung C.-C., Chen S.-C., et al. Association of hyperuricemia with renal outcomes, cardiovascular disease, and mortality. Clin J Am Soc Nephrol 2012, 7:541-548.
70. Iseki K., Ikemiya Y., Inoue T., Iseki C., Kinjo K., Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004, 44:642-650.
71. Weiner D.E., Tighiouart H., Elsayed E.F., Griffith J.L., Salem D.N., Levey A.S. Uric acid and incident kidney disease in the community. JAm Soc Nephrol 2008, 19:1204-1211.
72. Hsu C., Iribarren C., McCulloch C.E., Darbinian J., Go A.S. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med 2009, 169:342-350.
73. Ben-Dov I.Z., Kark J.D. Serum uric acid is a GFR-independent long-term predictor of acute and chronic renal insufficiency: the Jerusalem Lipid Research Clinic cohort study. Nephrol Dial Transpl 2011, 26:2558-2566.
74. Siu Y.-P., Leung K.-T., Tong M.K.-H., Kwan T.-H. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006, 47:51-59.
75. Kang D.-H., Nakagawa T., Feng L., et al. Arole for uric acid in the progression of renal disease. JAm Soc Nephrol 2002, 13:2888-2897.
76. Goicoechea M., de Vinuesa S.G., Verdalles U., et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010, 5:1388-1393.
77. Gonick H.C., Rubini M.E., Gleason I.O., Sommers S.C. The renal lesion in gout. Ann Intern Med 1965, 62:667-674.
78. Bose B., Badve S.V., Hiremath S.S., et al. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transpl 2013, 29(2):406-413.